scholarly journals Fibrinolytic therapy for COVID-19: a review of case series

Author(s):  
Hong-Long Ji ◽  
Yuling Dai ◽  
Runzhen Zhao
Author(s):  
Sidhi Laksono Purwowiyoto ◽  
Steven Phillip

Cardiovascular diseases (CVD) like myocardial infraction (MI) is still becoming the leading cause of morbidity and mortality and major problem in our healthcare system. Nowadays, revolution in high-tech medical treatment alongside with well-trained staff could decrease adverse event in ST elevation myocardial infarction (STEMI) patient. However, in developing country like Indonesia, those still become a challenge. Fibrinolytic therapy is still common practice even though primary percutaneous coronary intervention (PPCI) preferred. Intracranial bleeding is one of the most unfavorable effect after fibrinolytic therapy. Clinical should aware with clinical deterioration. Here we present case series of deadly intracranial haemorrhage in STEMI patient after fibrinolytic therapy.


2018 ◽  
Vol 24 ◽  
pp. 202-203
Author(s):  
Mireya Perez-Guzman ◽  
Alfredo Nava de la Vega ◽  
Arturo Pena Velarde ◽  
Tania Raisha Torres Victoria ◽  
Froylan Martinez-Sanchez ◽  
...  

VASA ◽  
2010 ◽  
Vol 39 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Grotenhermen

Background: To investigate the hypothesis that cases of arteritis similar to thromboangiitis obliterans (TAO) and associated with the use of cannabis were caused by cannabis or THC (dronabinol), or that cannabis use is a co-factor of TAO. Patients and methods: A systematic review on case reports and the literature on so-called cannabis arteritis, TAO, and cardiovascular effects of cannabinoids was conducted. Results: Fifteen reports with 57 cases of an arteritis associated with the use of cannabis and two additional case series of TAO, in which some patients also used cannabis, were identified. Clinical and pathological features of cannabis-associated arteritis do not differ from TAO and the major risk factor of TAO, tobacco use, was present in most, if not in all of these cases. The proposed pathophysiological mechanisms for the development of an arteritis by cannabis use are not substantiated. Conclusions: The hypothesis of cannabis being a causative factor or co-factor of TAO or an arteritis similar to TAO is not supported by the available evidence. The use of the term “cannabis arteritis” should be avoided until or unless more convincing scientific support is forthcoming.


2009 ◽  
Author(s):  
Emilie Thomas ◽  
Joaquin Poundja ◽  
Alain Brunet ◽  
Jacques Tremblay

Sign in / Sign up

Export Citation Format

Share Document